A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Trial Profile

A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Navitoclax (Primary)
  • Indications B cell lymphoma; Cutaneous T cell lymphoma; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 10 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 10 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 11 Jul 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top